Literature DB >> 7965775

Mangafodipir (MnDPDP)-and MnCl2-induced endothelium-dependent relaxation in bovine mesenteric arteries.

A Asplund1, D Grant, J O Karlsson.   

Abstract

Mn++ complexed to DPDP (N,N'-dipyridoxylethylenediamine-N,N'-diacetate-5,5'-bis(phosphate) generic name: mangafodipir), abbreviated MnDPDP, acts as an effective contrast enhancing agent for liver MRI. In clinical trials, a commonly reported side effect after i.v. administration of MnDPDP was facial flushing, most probably due to peripheral vasodilation. The present study was conducted to address possible mechanisms to explain the flushing effect. Nitric oxide is known to be stabilized in the presence of both uncomplexed and complexed Mn++ and this stabilization is probably due to the superoxide-scavenging properties of Mn++. The present study has demonstrated that both MnDPDP and MnCl2 relax phenylephrine precontracted bovine mesenteric artery strips in concentration-dependent manner. It was also found that a concentration of 10 microM MnDPDP, MnEDTA or MnCl2 gave approximately the same relaxation response as 0.1 microM acetylcholine. DPDP and EDTA had no appreciable intrinsic relaxation potential Mn(++)-induced relaxation was abolished when the endothelial layer was removed from the arteries. In addition, the Mn(++)-induced relaxation was attenuated by the nitric oxide synthase inhibitor N-nitro-arginine and the putative superoxide anion generator 6-anilino-5,8-quinolinedione, but not by the cyclooxygenase inhibitor indomethacin. Both N-nitro-arginine and 6-anilino-5,8-quinolinedione were found to induce an endothelium-dependent constriction of the bovine mesenteric artery strips. An approximately 2-fold increase in the intracellular concentration of cyclic GMP was detected after the addition of 10 microM MnDPDP or 0.1 microM acetylcholine. The increase in cyclic GMP coincided with the onset of relaxation and was effectively abolished by pretreatment with N-nitro-arginine.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7965775

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

1.  First clinical experience with the magnetic resonance imaging contrast agent and superoxide dismutase mimetic mangafodipir as an adjunct in cancer chemotherapy-a translational study.

Authors:  Jan Olof G Karlsson; Karin Adolfsson; Bo Thelin; Per Jynge; Rolf Gg Andersson; Ursula G Falkmer
Journal:  Transl Oncol       Date:  2012-02-01       Impact factor: 4.243

2.  Impact of repeated topical-loaded manganese-enhanced MRI on the mouse visual system.

Authors:  Shu-Wei Sun; Tiffany Thiel; Hsiao-Fang Liang
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-07-12       Impact factor: 4.799

3.  Effects of MnDPDP and ICRF-187 on Doxorubicin-Induced Cardiotoxicity and Anticancer Activity.

Authors:  Tino Kurz; Derek Grant; Rolf Gg Andersson; Robertson Towart; Michelandrea De Cesare; Jan Olof G Karlsson
Journal:  Transl Oncol       Date:  2012-08-01       Impact factor: 4.243

4.  Superior therapeutic index of calmangafodipir in comparison to mangafodipir as a chemotherapy adjunct.

Authors:  Jan Olof G Karlsson; Tino Kurz; Susanne Flechsig; Jacques Näsström; Rolf Gg Andersson
Journal:  Transl Oncol       Date:  2012-12-01       Impact factor: 4.243

Review 5.  Mangafodipir a Selective Cytoprotectant - with Special Reference to Oxaliplatin and Its Association to Chemotherapy-Induced Peripheral Neuropathy (CIPN).

Authors:  Jan Olof G Karlsson; Rolf Gg Andersson; Per Jynge
Journal:  Transl Oncol       Date:  2017-06-29       Impact factor: 4.243

Review 6.  ROS Modulator Molecules with Therapeutic Potential in Cancers Treatments.

Authors:  Carole Nicco; Frédéric Batteux
Journal:  Molecules       Date:  2017-12-31       Impact factor: 4.411

7.  Pretreatment with mangafodipir improves liver graft tolerance to ischemia/reperfusion injury in rat.

Authors:  Ismail Ben Mosbah; Yann Mouchel; Julie Pajaud; Catherine Ribault; Catherine Lucas; Alexis Laurent; Karim Boudjema; Fabrice Morel; Anne Corlu; Philippe Compagnon
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

8.  Oxidant Stress and Acetaminophen Hepatotoxicity: Mechanism-Based Drug Development.

Authors:  Anup Ramachandran; Hartmut Jaeschke
Journal:  Antioxid Redox Signal       Date:  2021-07-07       Impact factor: 7.468

Review 9.  MnDPDP: Contrast Agent for Imaging and Protection of Viable Tissue.

Authors:  Per Jynge; Arne M Skjold; Ursula Falkmer; Rolf G G Andersson; John G Seland; Morten Bruvold; Viggo Blomlie; Willy Eidsaunet; Jan O G Karlsson
Journal:  Contrast Media Mol Imaging       Date:  2020-09-04       Impact factor: 3.161

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.